medigraphic.com
ISSN 1561-3038 (Print)

2021, Number 2

<< Back

Rev Cubana Med Gen Integr 2021; 37 (2)

HeberFERON® treatment of basal cell carcinoma in Primary Healthcare in Cuba

Veja AJ, Álvarez FA, Ventura NK, Fernández HA, Nodal TS

Language: Spanish
References: 12
Page: 1-13
PDF size: 473.97 Kb.


ABSTRACT

Introduction: Skin cancer is the commonest type of cancer in humans. Basal cell carcinoma is the commonest of all skin cancers, accounting for 80% to 90% of all cases. Exceptionally, they metastasize, but can cause significant morbidity and involve younger ages. They are successfully treated by surgery, radiotherapy, chemotherapy and cryotherapy, mostly at the secondary level of health. However, these treatments are not always possible or desirable. HeberFERON® is a combination of recombinant human alpha and gamma interferons, which has been shown to produce synergistic effects in reducing the proliferation of several lines of cancer cells. This formulation has been approved in Cuba for treating basal cell carcinoma.
Case presentation: Three cases are presented with a diagnosis of basal cell carcinoma, located on the face, treated with HeberFERON®. In two cases, the lesion was observed to disappear at the end of the third week of treatment. In the third case, an 84-year-old woman, at the end of the first cycle of treatment, the size of the treated lesion was reduced and another adjacent lesion disappeared, which did not receive direct treatment. In this patient, the residual lesion was assessed by ultrasound to determine its extension and depth. In the three cases, the adverse reactions were mild and transitory.
Conclusions: HeberFERON® is an effective and safe option for treating basal cell carcinoma in primary health care in Cuba.


REFERENCES

  1. Bello Rivero I. A Synergistic immunotherapy for skin cancer. Health and Medicine. 2017 [acceso: 14/05/2019]. Disponible en: http://www.scientia.global/professor-iraldo-bello-rivero-synergistic-immunotherapy-skin-cancer/

  2. Viñas García M, Algozaín Acosta Y, Álvarez Campos L, Quintana Díaz JC. Comportamiento del carcinoma basocelular facial en Artemisa durante la última década. Rev Cuba Estomatol. 2011 [acceso: 04/02/2019];48(2):121-8. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S0034-75072011000200004&lng=es&nrm=iso&tlng=es

  3. Bello I, García Y, Duncan Y, Vázquez D, Santana H, Besada V, et al. HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Seminars in Oncology. 2018;45:27-33. DOI: https://doi.org/10.1053/j.seminoncol.2018.04.007

  4. Bello-Álvarez C, Vázquez-Blomquist D, Miranda J, García Y, Novoa LI, Palenzuela D, et al. Regulation by IFN-a/IFN-? co-formulation (HerberPAG(r)) of genes involved in interferon-STAT-pathways and apoptosis in U87MG. Curr Top Med Chem. 2014 [acceso: 14/01/2015];14(3). Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/24304312

  5. Bello-Alvarez C. Quantification of mRNA in malignant glioma (U-87 cell line) in vitro model treated with the combination of interferon alpha2b and gamma IFNs [tesis]. Havana University: CIGB; 2011

  6. Fahradyan A, Howell A, Wolfswinkel E, Tsuha M, Sheth P, Wong A. Updates on the management of non-melanoma skin cancer (NMSC). Healthcare. 2017;5(82):1-24. Disponible en: https://doi:10.3390/healthcare5040082

  7. Anasagati L, García Y, Collazo S, Jiménez Y, Tijerino E, Ballester Y, et al. HeberFERON, formulation based on IFNs alpha2b and gamma for the treatment of non-melanoma skin cancer. AMJ. 2017;10(6):509-15. DOI: https://doi.org/10.21767/AMJ.2017.3013

  8. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. J Interferon Cytokine Res 2011;31:545-52.

  9. Almazán-Moga A, Zarzosa P, Molist C, Velasco P, Pyczek J, Simon-Keller K, et al. Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands. British Journal of Cancer. 2017 [acceso: 14/05/2019];117:1314-25. Disponible en: https://www.nature.com/articles/bjc2017305

  10. Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-Reactive Protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A Systematic Review. PLoS ONE. 2015 [acceso: 14/05/2019];10(12):e0143080. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705106/pdf/pone.0143080.pdf

  11. Schwartz L, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST1.1 Update and Clarification: From the RECIST Committee. Eur J Cancer. 2016;62:132-7. DOI: https://doi.org/10.1016/j.ejca.2016.03.081

  12. González C. Caracterización de las lesiones dermatológicas por ecografía. Rev. Colomb. Radiol. 2014 [acceso: 14/05/2019];25(3):4006-14. Disponible en: http://webcir.org/revistavirtual/articulos/noviembre14/colombia/caracterizacion_de_lesiones_colombia_esp.pdf




2020     |     www.medigraphic.com